Study identifier:NIS-RME-XXX-2014/1
ClinicalTrials.gov identifier:NCT02153411
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluation of aSthma Management in Middle EAst Adult population
asthma
N/A
No
-
All
7294
Observational
18 Years - 130 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
Descriptive study on the management of asthma in asthmatic Middle East adult population : Algeria,Egypt, Irak,Iran, Jordan, Koweit, Lebanon, Qatar,Saudi,Tunisia, UAE
Multicentric, transversal, descriptive, epidemiological study, conducted in a random sample of general practitioner and medical specialist (Pulmonologist and/or allergologist) in the public and the private sector.
Location
Location
TUNIS, NIS-RME-XXX-2014/1, Tunisia
Location
SOUSSE, NIS-RME-XXX-2014/1, Tunisia
Location
SFAX, NIS-RME-XXX-2014/1, Tunisia
Location
Al Khobar, NIS-RME-XXX-2014/1, Saudi Arabia
Location
Riyadh, NIS-RME-XXX-2014/1, Saudi Arabia
Location
Jeddah, NIS-RME-XXX-2014/1, Saudi Arabia
Location
Al Hada, NIS-RME-XXX-2014/1, Saudi Arabia
Location
Dammam, NIS-RME-XXX-2014/1, Saudi Arabia
Arms | Assigned Interventions |
---|---|
8645 asthmatic patients Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.